IGC Pharma Completes Enrollment in Phase 2 CALMA Trial
POTOMAC, Md., June 10, 2026 IGC Pharma, Inc. (NYSE American: IGC) announced that its Phase 2 CALMA clinical trial...
Neurodegenerative Disease
Advertisement
AlzeCure and Eli Lilly Partner on Alzheimer’s Drug ACD680
STOCKHOLM, Sweden, June 9, 2026 AlzeCure Pharma announced a global collaboration and out-licensing agreement with Eli Lilly and Company...
Bial Discontinues Pariceract After Phase 2b ACTIVATE Trial Miss
PORTO, Portugal, June 9, 2026 Bial announced topline results from its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract)...
Coya Therapeutics Begins Blinded Extension Phase of ALSTARS Trial for COYA 302 in ALS
HOUSTON, Texas, June 8, 2026 Coya Therapeutics, Inc. announced a significant milestone in the ongoing ALSTARS clinical trial, with...
Teva Reports New AUSTEDO Data in Huntington’s Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals has presented new real-world evidence demonstrating that treatment...
Advertisements
NanoDetection and Oligomerix Partner to Advance Tau-Based Neurodegenerative Diagnostics
FRANKLIN, Ohio & BRONX, N.Y., June 2026 NanoDetection Technology (NDT) and Oligomerix announced an exclusive worldwide licensing agreement granting...
TOBY Gains FDA Breakthrough Status for Alzheimer’s Test
AUSTIN, Texas, May 26, 2026 TOBY, Inc., a biotechnology company focused on non-invasive disease detection technologies, has announced that...
Ono Pharma Highlights New Phase 2 MSA Data
OSAKA, Japan — May 28, 2026 Ono Pharmaceutical Co., Ltd. announced the presentation of new clinical data from its...
TreeFrog’s TFG-001 Shows Strong Parkinson’s Recovery Data
BORDEAUX, France, May 25, 2026 TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell...
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
Advertisement
